×
About 7,120 results

ALLMedicine™ Glomerulonephritis Center

Research & Reviews  2,451 results

Bartter-like syndrome induced by tacrolimus in a renal transplanted boy: A Case Report.
https://doi.org/10.2174/1574886317666220518085725
Current Drug Safety; Dias RF, Monteiro MDC et. al.

May 21st, 2022 - Losing-salt tubulopathies, such as Bartter syndrome, are rare and usually inherited due to mutations of tubular reabsorption channels of the nephrons. Despite its scarcity, some cases of acquired losing-salt tubulopathies have been described. In t...

Immune System Related Kidney Disease
https://clinicaltrials.gov/ct2/show/NCT00001979

May 20th, 2022 - This study evaluates participants with known or suspected immunologically-mediated kidney diseases, including but not limited to nephrotic syndrome, glomerulonephritis, membranous nephropathy, lupus nephritis, and nephritis associated with other s...

Assessment of renal microcirculation in biopsy-proven tubulointerstitial nephritis in p...
https://doi.org/10.1016/j.mvr.2022.104379
Microvascular Research; Gigante A, Lai S et. al.

May 20th, 2022 - Renal resistive index (RRI) measured by Doppler sonography is a marker of microvascular status and it is associated with changes in renal function. Aim of the study was to assess RRI in biopsy-proven tubulointerstitial nephritis (TIN) in patients ...

Dermatologic Manifestations of Homocystinuria
https://emedicine.medscape.com/article/1115062-print

May 17th, 2022 - Practice Essentials Homocystinuria is an inherited autosomal recessive defect in methionine metabolism that is caused by a deficiency in cystathionine synthase.[1] This defect leads to a multisystemic disorder of the connective tissue, muscles, CN...

Dermatologic Manifestations of Homocystinuria
http://emedicine.medscape.com/article/1115062-overview

May 17th, 2022 - Practice Essentials Homocystinuria is an inherited autosomal recessive defect in methionine metabolism that is caused by a deficiency in cystathionine synthase. [1] This defect leads to a multisystemic disorder of the connective tissue, muscles, C...

see more →

Guidelines  6 results

2022 American College of Rheumatology/European Alliance of Associations for Rheumatolog...
https://doi.org/10.1002/art.41983
Arthritis & Rheumatology (Hoboken, N.J.); Suppiah R, Robson JC et. al.

Feb 3rd, 2022 - To develop and validate classification criteria for microscopic polyangiitis (MPA). Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in 5 phases: 1) identification of candidate items ...

A digest of the evidence-based Clinical Practice Guideline for Rapidly Progressive Glom...
https://doi.org/10.1007/s10157-021-02096-7
Clinical and Experimental Nephrology; Usui J, Kawashima S et. al.

Sep 27th, 2021 - A digest of the evidence-based Clinical Practice Guideline for Rapidly Progressive Glomerulonephritis 2020.|2021|Usui J,Kawashima S,Sada KE,Miyawaki Y,Nakazawa D,|diagnosis,drug therapy,

Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.
https://doi.org/10.1016/j.kint.2021.05.015
Kidney International; Rovin BH, Adler SG et. al.

Sep 25th, 2021 - The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Glomerular Diseases is an update to the KDIGO 2012 guideline. The aim is to assist clinicians caring for individuals with glomerulonephritis (G...

Evidence-based clinical practice guidelines for rapidly progressive glomerulonephritis ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891375
Clinical and Experimental Nephrology; Arimura Y, Muso E et. al.

Apr 22nd, 2016 - Evidence-based clinical practice guidelines for rapidly progressive glomerulonephritis 2014.|2016|Arimura Y,Muso E,Fujimoto S,Hasegawa M,Kaname S,|standards,diagnosis,epidemiology,physiopathology,therapy,standards,

Treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGO.
https://doi.org/10.1007/s00467-012-2304-8
Pediatric Nephrology (Berlin, Germany); Lombel RM, Hodson EM et. al.

Oct 12th, 2012 - Kidney Disease: Improving Global Outcomes (KDIGO) recently published the clinical practice guideline on glomerulonephritis (GN) to assist the practitioner caring for patients with GN. Chapter 4 of the guideline focuses on managing children aged 1-...

see more →

Drugs  209 results see all →

Clinicaltrials.gov  40 results

Immune System Related Kidney Disease
https://clinicaltrials.gov/ct2/show/NCT00001979

May 20th, 2022 - This study evaluates participants with known or suspected immunologically-mediated kidney diseases, including but not limited to nephrotic syndrome, glomerulonephritis, membranous nephropathy, lupus nephritis, and nephritis associated with other s...

Huaiqihuang Granule in CKD Stage 3 Primary Glomerulonephritis
https://clinicaltrials.gov/ct2/show/NCT04263922

Mar 15th, 2022 - Chronic kidney disease is a common disease that affects health seriously. In some regions of China, the morbidity of this kind of disease is as high as 10.8%. Primary glomerulopathy is one of the pathogenesis of chronic kidney disease, which occup...

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
https://clinicaltrials.gov/ct2/show/NCT05067127

Mar 9th, 2022 - This is a Phase 3 study to assess the efficacy and safety of twice-weekly subcutaneous (SC) doses of pegcetacoplan compared to placebo in patients with C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN) on...

Study of the Link Between Complement Activation and IgA Nephropathy Severity
https://clinicaltrials.gov/ct2/show/NCT05234463

Mar 2nd, 2022 - IgA nephropathy (IgAN) is a common cause of glomerulonephritis and a major cause of end stage renal disease in up to 20-40% of patients. However, its prognosis still cannot be accurately predicted due to the high heterogenicity of clinical present...

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
https://clinicaltrials.gov/ct2/show/NCT05126277

Feb 9th, 2022 - This trial will evaluate the efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or ianalumab given every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN ...

see more →

News  138 results

How a Low-Protein Diet Can Delay Dialysis in Patients With Chronic Kidney Disease
https://www.medscape.com/viewarticle/961722

Nov 5th, 2021 - At any given time, an estimated 15% of the US adult population has chronic kidney disease (CKD). It manifests as reduced kidney function to below 60% of its normal range (estimated glomerular filtration rate < 60 mL/min/1.73 m2) or by spillage of ...

EU Looking Into New Possible Side Effects of MRNA COVID-19 Shots
https://www.medscape.com/viewarticle/956419

Aug 12th, 2021 - (Reuters) - Three new conditions reported by a small number of people after vaccination with COVID-19 shots from Pfizer and Moderna are being studied to assess if they may be possible side-effects, Europe's drugs regulator said on Wednesday. Eryth...

TAVI Safe and Effective in Patients With Inflammatory Bowel Disease
https://www.medscape.com/viewarticle/954929

Jul 19th, 2021 - NEW YORK (Reuters Health) - Transcatheter aortic-valve implantation (TAVI) is safe and effective for patients with inflammatory bowel disease (IBD), according to what is believed to be the first study to assess TAVI outcomes in this patient popula...

Complement Inhibitor Shows Early Promise in IgA Nephropathy
https://www.medscape.com/viewarticle/952739

Jun 9th, 2021 - A first-in-class oral inhibitor of the alternative complement pathway that drives the pathogenesis of primary glomerulonephritis, iptacopan (LNP023, Novartis), is showing early promise as the first targeted therapy for the treatment of IgA nephrop...

Lower glucocorticoid dose proves effective for new-onset ANCA-associated vasculitis
https://www.mdedge.com/rheumatology/article/240827/lupus-connective-tissue-diseases/lower-glucocorticoid-dose-proves
Steve Cimino

Jun 1st, 2021 - A reduced dose of prednisolone plus rituximab was as effective as a conventionally high dose in treating patients with newly diagnosed antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis, according to a new Japanese study, along with.

see more →

Patient Education  4 results see all →